Novartis OTC Plant Troubled By Quality Failures A Year After Shutdown
This article was originally published in The Tan Sheet
Executive Summary
FDA recorded nine observations – many of them repeats from 2011 and 2012 – on a form 483 during its early 2013 visit to Novartis Consumer Health’s facility in Lincoln, Nebraska. The observations cited inadequate consumer complaint handling and container closure stability testing.